Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 9589 to 9590 of 9590 entries
Sorted by: Best Match Show Resources per page
Myristoylation-mediated phase separation of EZH2 compartmentalizes STAT3 to promote lung cancer growth.

Cancer letters

Zhang J, Zeng Y, Xing Y, Li X, Zhou L, Hu L, Chin YE, Wu M.
PMID: 34102285
Cancer Lett. 2021 Sep 28;516:84-98. doi: 10.1016/j.canlet.2021.05.035. Epub 2021 Jun 05.

N-myristoylation is a crucial signaling and pathogenic modification process that confers hydrophobicity to cytosolic proteins. Although different large-scale approaches have been applied, a large proportion of myristoylated proteins remain to be identified. EZH2 is overexpressed in lung cancer cells...

Cite
Zhang J, Zeng Y, Xing Y, et al. Myristoylation-mediated phase separation of EZH2 compartmentalizes STAT3 to promote lung cancer growth. Cancer Lett. 2021;516:84-98doi: 10.1016/j.canlet.2021.05.035.
Zhang, J., Zeng, Y., Xing, Y., Li, X., Zhou, L., Hu, L., Chin, Y. E., & Wu, M. (2021). Myristoylation-mediated phase separation of EZH2 compartmentalizes STAT3 to promote lung cancer growth. Cancer letters, 51684-98. https://doi.org/10.1016/j.canlet.2021.05.035
Zhang, Jie, et al. "Myristoylation-mediated phase separation of EZH2 compartmentalizes STAT3 to promote lung cancer growth." Cancer letters vol. 516 (2021): 84-98. doi: https://doi.org/10.1016/j.canlet.2021.05.035
Zhang J, Zeng Y, Xing Y, Li X, Zhou L, Hu L, Chin YE, Wu M. Myristoylation-mediated phase separation of EZH2 compartmentalizes STAT3 to promote lung cancer growth. Cancer Lett. 2021 Sep 28;516:84-98. doi: 10.1016/j.canlet.2021.05.035. Epub 2021 Jun 05. PMID: 34102285.
Copy Download .nbib Format: NLM
Antibody screening at reduced pH enables preferential selection of potently neutralizing antibodies targeting SARS-CoV-2.

AIChE journal. American Institute of Chemical Engineers

Madan B, Reddem ER, Wang P, Casner RG, Nair MS, Huang Y, Fahad AS, de Souza MO, Banach BB, López Acevedo SN, Pan X, Nimrania R, Teng IT, Bahna F, Zhou T, Zhang B, Yin MT, Ho DD, Kwong PD, Shapiro L, DeKosky BJ.
PMID: 34898670
AIChE J. 2021 Dec;67(12):e17440. doi: 10.1002/aic.17440. Epub 2021 Oct 04.

Antiviral monoclonal antibody (mAb) discovery enables the development of antibody-based antiviral therapeutics. Traditional antiviral mAb discovery relies on affinity between antibody and a viral antigen to discover potent neutralizing antibodies, but these approaches are inefficient because many high affinity...

Cite
Madan B, Reddem ER, Wang P, et al. Antibody screening at reduced pH enables preferential selection of potently neutralizing antibodies targeting SARS-CoV-2. AIChE J. 2021;67(12):e17440doi: 10.1002/aic.17440.
Madan, B., Reddem, E. R., Wang, P., Casner, R. G., Nair, M. S., Huang, Y., Fahad, A. S., de Souza, M. O., Banach, B. B., López Acevedo, S. N., Pan, X., Nimrania, R., Teng, I. T., Bahna, F., Zhou, T., Zhang, B., Yin, M. T., Ho, D. D., Kwong, P. D., Shapiro, L., & DeKosky, B. J. (2021). Antibody screening at reduced pH enables preferential selection of potently neutralizing antibodies targeting SARS-CoV-2. AIChE journal. American Institute of Chemical Engineers, 67(12), e17440. https://doi.org/10.1002/aic.17440
Madan, Bharat, et al. "Antibody screening at reduced pH enables preferential selection of potently neutralizing antibodies targeting SARS-CoV-2." AIChE journal. American Institute of Chemical Engineers vol. 67,12 (2021): e17440. doi: https://doi.org/10.1002/aic.17440
Madan B, Reddem ER, Wang P, Casner RG, Nair MS, Huang Y, Fahad AS, de Souza MO, Banach BB, López Acevedo SN, Pan X, Nimrania R, Teng IT, Bahna F, Zhou T, Zhang B, Yin MT, Ho DD, Kwong PD, Shapiro L, DeKosky BJ. Antibody screening at reduced pH enables preferential selection of potently neutralizing antibodies targeting SARS-CoV-2. AIChE J. 2021 Dec;67(12):e17440. doi: 10.1002/aic.17440. Epub 2021 Oct 04. PMID: 34898670; PMCID: PMC8646896.
Copy Download .nbib Format: NLM
Showing 9589 to 9590 of 9590 entries